RU2014128455A - UNIVERSAL CARDIOPLEGIC SOLUTION (OPTIONS) - Google Patents

UNIVERSAL CARDIOPLEGIC SOLUTION (OPTIONS) Download PDF

Info

Publication number
RU2014128455A
RU2014128455A RU2014128455A RU2014128455A RU2014128455A RU 2014128455 A RU2014128455 A RU 2014128455A RU 2014128455 A RU2014128455 A RU 2014128455A RU 2014128455 A RU2014128455 A RU 2014128455A RU 2014128455 A RU2014128455 A RU 2014128455A
Authority
RU
Russia
Prior art keywords
cardioplegic solution
pharmaceutically acceptable
ions
mannitol
mmol
Prior art date
Application number
RU2014128455A
Other languages
Russian (ru)
Other versions
RU2574957C1 (en
Inventor
Валентин Евгеньевич Вольгушев
Original Assignee
Общество С Ограниченной Ответственностью "Кардиосистемфарма" (Ооо "Ксф")
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Кардиосистемфарма" (Ооо "Ксф") filed Critical Общество С Ограниченной Ответственностью "Кардиосистемфарма" (Ооо "Ксф")
Priority claimed from RU2014128455/15A external-priority patent/RU2574957C1/en
Priority to RU2014128455/15A priority Critical patent/RU2574957C1/en
Priority to BR112017000052-0A priority patent/BR112017000052B1/en
Priority to ES15819585T priority patent/ES2713434T3/en
Priority to US15/325,501 priority patent/US10646511B2/en
Priority to JP2017522314A priority patent/JP6629850B2/en
Priority to MX2017000438A priority patent/MX2017000438A/en
Priority to TR2019/01995T priority patent/TR201901995T4/en
Priority to CN202211187936.0A priority patent/CN115813947A/en
Priority to CN201580037619.2A priority patent/CN106659677A/en
Priority to EA201700032A priority patent/EA035702B1/en
Priority to PCT/RU2015/000353 priority patent/WO2016007041A1/en
Priority to EP15819585.9A priority patent/EP3167874B1/en
Publication of RU2014128455A publication Critical patent/RU2014128455A/en
Publication of RU2574957C1 publication Critical patent/RU2574957C1/en
Application granted granted Critical
Priority to US16/843,376 priority patent/US10987378B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

1. Кардиоплегический раствор, представляющий собой водный раствор, содержащий, ммоль/л:Ионы калия 40,2-200,1Ионы магния 0-24,3с pH раствора 7,1-8,9, который обеспечивается путем добавления фармацевтически приемлемых основания и кислоты.2. Кардиоплегический раствор, представляющий собой водный раствор, содержащий, ммоль/л:Ионы калия 40,2-200,1Ионы магния 0-24,3Фармацевтически приемлемый диуретик, обеспечивающий осмолярность в пределах 275-460 мОсм/кг,с pH раствора 7,1-8,9, который обеспечивается путем добавления фармацевтически приемлемых основания и кислоты.3. Кардиоплегический раствор по п. 2, характеризующийся тем, что получен из следующих компонентов:Хлорид калия, г 7,45Сульфат магния, г 2,34Трометамол, г 0,5Маннитол, г 5,9Дистиллированная вода, мл до 1000, при условии введения 1 М хлористо-водородной кислоты до установления pH 7,6-8,0.4. Кардиоплегический раствор по п. 2, характеризующийся тем, что получен из следующих компонентов:Хлорид калия, г 8,38;Сульфат магния, г 2,34;Трометамол, г 0,5;Маннитол, г 35,9;Дистиллированная вода, мл до 1000,при условии введения 1 М хлористо-водородной кислоты до установления pH 7,6-8,0.1. Cardioplegic solution, which is an aqueous solution containing, mmol / l: Potassium ions 40.2-200.1 Magnesium ions 0-24.3 s pH of 7.1-8.9, which is achieved by adding pharmaceutically acceptable base and acid .2. Cardioplegic solution, which is an aqueous solution containing, mmol / L: Potassium ions 40.2-200.1 Magnesium ions 0-24.3 Pharmaceutically acceptable diuretic, providing an osmolarity in the range of 275-460 mOsm / kg, with a pH of 7.1- 8.9, which is achieved by the addition of pharmaceutically acceptable bases and acids. 3. The cardioplegic solution according to claim 2, characterized in that it is obtained from the following components: Potassium chloride, g 7.45 Magnesium sulfate, g 2.34 Tromethamol, g 0.5 Mannitol, g 5.9 Distilled water, ml up to 1000, provided that 1 M is introduced hydrochloric acid to establish a pH of 7.6-8.0.4. Cardioplegic solution according to claim 2, characterized in that it is obtained from the following components: Potassium chloride, g 8.38; Magnesium sulfate, g 2.34; Tromethamol, g 0.5; Mannitol, g 35.9; Distilled water, ml up to 1000, subject to the introduction of 1 M hydrochloric acid to establish a pH of 7.6-8.0.

Claims (4)

1. Кардиоплегический раствор, представляющий собой водный раствор, содержащий, ммоль/л:1. Cardioplegic solution, which is an aqueous solution containing, mmol / l: Ионы калия 40,2-200,1 Potassium ions 40.2-200.1 Ионы магния 0-24,3 Magnesium ions 0-24.3 с pH раствора 7,1-8,9, который обеспечивается путем добавления фармацевтически приемлемых основания и кислоты.with a pH of 7.1-8.9, which is provided by the addition of pharmaceutically acceptable bases and acids. 2. Кардиоплегический раствор, представляющий собой водный раствор, содержащий, ммоль/л:2. Cardioplegic solution, which is an aqueous solution containing, mmol / l: Ионы калия 40,2-200,1 Potassium ions 40.2-200.1 Ионы магния 0-24,3 Magnesium ions 0-24.3 Фармацевтически приемлемый диуретик, обеспечивающий осмолярность в пределах 275-460 мОсм/кг,A pharmaceutically acceptable diuretic providing an osmolarity in the range of 275-460 mOsm / kg, с pH раствора 7,1-8,9, который обеспечивается путем добавления фармацевтически приемлемых основания и кислоты.with a pH of 7.1-8.9, which is provided by the addition of pharmaceutically acceptable bases and acids. 3. Кардиоплегический раствор по п. 2, характеризующийся тем, что получен из следующих компонентов:3. Cardioplegic solution according to claim 2, characterized in that it is obtained from the following components: Хлорид калия, г 7,45Potassium chloride, g 7.45 Сульфат магния, г 2,34Magnesium sulfate, g 2.34 Трометамол, г 0,5Trometamol, g 0.5 Маннитол, г 5,9Mannitol, g 5.9 Дистиллированная вода, мл до 1000, при условии введения 1 М хлористо-водородной кислоты до установления pH 7,6-8,0.Distilled water, ml up to 1000, subject to the introduction of 1 M hydrochloric acid to establish a pH of 7.6-8.0. 4. Кардиоплегический раствор по п. 2, характеризующийся тем, что получен из следующих компонентов:4. Cardioplegic solution according to claim 2, characterized in that it is obtained from the following components: Хлорид калия, г 8,38;Potassium chloride, g 8.38; Сульфат магния, г 2,34;Magnesium sulfate, g 2.34; Трометамол, г 0,5;Trometamol, g 0.5; Маннитол, г 35,9;Mannitol, g 35.9; Дистиллированная вода, мл до 1000,Distilled water, ml up to 1000, при условии введения 1 М хлористо-водородной кислоты до установления pH 7,6-8,0. subject to the introduction of 1 M hydrochloric acid to establish a pH of 7.6-8.0.
RU2014128455/15A 2014-07-11 2014-07-11 Cardioplegic solution (versions) RU2574957C1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
RU2014128455/15A RU2574957C1 (en) 2014-07-11 Cardioplegic solution (versions)
TR2019/01995T TR201901995T4 (en) 2014-07-11 2015-06-05 Universal cardioplegic solution (variants).
CN201580037619.2A CN106659677A (en) 2014-07-11 2015-06-05 Universal cardioplegic solution (variants)
US15/325,501 US10646511B2 (en) 2014-07-11 2015-06-05 Universal cardioplegic solution (variants)
JP2017522314A JP6629850B2 (en) 2014-07-11 2015-06-05 General-purpose cardioplegic solution (variant)
MX2017000438A MX2017000438A (en) 2014-07-11 2015-06-05 Universal cardioplegic solution (variants).
BR112017000052-0A BR112017000052B1 (en) 2014-07-11 2015-06-05 CARDIOPLEGIC SOLUTIONS TO ACHIEVE AND MAINTAIN ASYSTOLY ACHIEVED IN BLOOD CARDIOPLEGIA
CN202211187936.0A CN115813947A (en) 2014-07-11 2015-06-05 General cardioplegic solution (variants)
ES15819585T ES2713434T3 (en) 2014-07-11 2015-06-05 Universal cardioplegic solution (variants)
EA201700032A EA035702B1 (en) 2014-07-11 2015-06-05 Universal cardioplegic solution (variants)
PCT/RU2015/000353 WO2016007041A1 (en) 2014-07-11 2015-06-05 Universal cardioplegic solution (variants)
EP15819585.9A EP3167874B1 (en) 2014-07-11 2015-06-05 Universal cardioplegic solution (variants)
US16/843,376 US10987378B2 (en) 2014-07-11 2020-04-08 Universal cardioplegic solution (variants)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2014128455/15A RU2574957C1 (en) 2014-07-11 Cardioplegic solution (versions)

Publications (2)

Publication Number Publication Date
RU2014128455A true RU2014128455A (en) 2016-02-10
RU2574957C1 RU2574957C1 (en) 2016-02-10

Family

ID=

Also Published As

Publication number Publication date
EA035702B1 (en) 2020-07-28
BR112017000052B1 (en) 2022-09-13
US20170143760A1 (en) 2017-05-25
ES2713434T3 (en) 2019-05-21
EP3167874A1 (en) 2017-05-17
JP6629850B2 (en) 2020-01-15
EA201700032A1 (en) 2017-05-31
BR112017000052A2 (en) 2017-11-07
TR201901995T4 (en) 2019-03-21
EP3167874B1 (en) 2018-12-26
CN106659677A (en) 2017-05-10
US10987378B2 (en) 2021-04-27
JP2017520629A (en) 2017-07-27
EP3167874A4 (en) 2017-12-27
US10646511B2 (en) 2020-05-12
MX2017000438A (en) 2017-08-16
WO2016007041A1 (en) 2016-01-14
US20200230171A1 (en) 2020-07-23
CN115813947A (en) 2023-03-21

Similar Documents

Publication Publication Date Title
WO2016080645A3 (en) Ammonia synthesis apparatus
EA201790727A1 (en) METHOD OF OBTAINING DIOL
MY190283A (en) Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
RU2016148241A (en) SYNTHESIS OF ZINC COMPLEX WITH LISIN FROM ZINC CHLORIDE
EA201691825A1 (en) STABILIZED SOLUTION ON THE BASIS OF ACTIVE SUBSTANCES, METHOD FOR OBTAINING A STABILIZED SOLUTION OF ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITION ON THE BASIS OF A STABILIZED SOLUTION OF ACTIVE SUBSTANCES (TWO OPTIONS)
RU2014128455A (en) UNIVERSAL CARDIOPLEGIC SOLUTION (OPTIONS)
EA201791175A1 (en) EMULGER PARTICLES AND METHODS FOR THEIR PRODUCTION AND USE
RU2017111801A (en) PHARMACEUTICAL COMPOSITION BASED ON A CONDENSED DERIVATIVE AMINODIHYDROTHIAZINE
IN2014MU03425A (en)
PH12018502693A1 (en) Crystal of amino acid salt of 3-hydroxyisovaleric acid and production method thereof
RU2009126331A (en) CRYSTALLOID CARDIOPLEGIC SOLUTION
RU2014108338A (en) DISINFECTANT COMPOSITION
MX2017007376A (en) Process for producing 4-azidosulfonylphthalic anhydride.
RU2013136340A (en) NUTRITION FOR YEAST SACCHAROMYCES CEREVISIAE AND METHOD OF ITS USE
RU2016116891A (en) METHOD OF CARRYOPLOGY
EA201890976A1 (en) LIQUID WASHING CONCENTRATE
RU2015118465A (en) The method of obtaining 8-nitroquinoline-2-carboxylic acid
RU2016135387A (en) Flotation solution for the diagnosis of intestinal helminthiases
BR112015025785A2 (en) stable aerated food product and process for preparing the same
RU2013135818A (en) METHOD FOR ELECTROLYSIS OF AQUEOUS SALT SOLUTION
RU2012135438A (en) METHOD FOR ELECTROLYSIS OF AQUEOUS SALT SOLUTION
TH2001003018A (en) Value creation of potassium salts co-produced in the fermentation process
RU2013152580A (en) METHOD FOR OBTAINING ADEMETHIONINE DOUBLE SALT WITH SULFUR AND N-TOLUOLSULFO ACID
Li et al. Chichibabin pyridine synthesis
MX2016016260A (en) New solid forms of sitagliptin.